Diminished ovarian reserve in the United States assisted reproductive technology population Diagnostic trends among 181536 cycles from the Society for Assisted Reproductive Technology Clinic Outcomes Reporting System
Tuesday, September 1, 2015Diminished ovarian reserve (DOR) assignment increased 7% among all Society for Assisted Reproductive Technology Clinic Outcomes Reporting System cycles from 2004 to 2011, despite minimal increase in patient age at cycle start. The ability of DOR assignment to predict poor ovarian response worsened.
Wednesday, April 29, 2015Reflections on "Does antral follicle count (AFC) predict pregnancy rates in unstimulated therapeutic donor insemination (TDI) cycles?" by Ripley et al.
Unraveling the fertility knot in World Health Organization type 2 anovulatory women Another step toward a pharmacogenetic treatment choice
Monday, March 30, 2015Reflections on "FSH receptor polymorphism affects the outcome of ovulation induction in normogonadotropic (WHO2) anovulatory infertility" by Valkenburg et al.
Tuesday, November 25, 2014Women with blood type O had a reduced likelihood of diminished ovarian reserve, but women with blood type B or AB had an increased risk.
Thursday, February 20, 2014Education and enhanced awareness of the effect of age on fertility is essential in counseling the patient who desires pregnancy.
Wednesday, November 27, 2013No relationship could be demonstrated between blood type and risk of diminished ovarian reserve in an analysis of 305 patients undertaking in vitro fertilization.
FSHB 211 and FSHR 2039 are associated with serum levels of follicle stimulating hormone and antimüllerian hormone in healthy girls a longitudinal cohort study
Monday, September 30, 2013FSHB GG+FSHR AA is the most favorable genotype for male gonadal function, but it has never been evaluated in girls. Healthy girls with this genotype have increased follicle-stimulating hormone and reduced antimüllerian hormone.
Why we may abandon basal follicle stimulating hormone testing A sea change in determining ovarian reserve using antimüllerian hormone
Friday, May 31, 2013Antimullerian hormone is a more informative and therefore a better serum test of ovarian reserve than basal FSH.
Friday, May 31, 2013Reflections on "Why we may abandon basal follicle-stimulating hormone testing: A sea change in determining ovarian reserve using antimullerian hormone" by Toner et al.
Antimüllerian hormone levels decrease in women using combined contraception independently of administration route
Thursday, March 28, 2013In young healthy, normal weight women, continuous use of combined contraception leads to a decrease in serum AMH levels independently of administration route.
Polymorphisms in gonadotropin and gonadotropin receptor genes as markers of ovarian reserve and response in in vitro fertilization
Monday, March 18, 2013Some genetic polymorphisms are associated with ovarian response to gonadotropin administration and exhibit potential for a pharmacogenetic approach in ovarian stimulation. In contrast, ovarian reserve seems to be independent of gonadotropin variants.
Addition of recombinant follicle-stimulating hormone to human chorionic gonadotropin treatment in adolescents and young adults with hypogonadotropic hypogonadism promotes normal testicular growth…
Thursday, September 27, 2012Adding recombinant follicle-stimulating hormone to human chorionic gonadotropin treatment protocols in adolescent/young adult men with hypogonadotropic hypogonadism results in normal testicular growth and may hasten induction of spermatogenesis.
High frequency of discordance between antimullerian hormone and follicle stimulating hormone levels in serum from estradiol confirmed days 2 to 4 of the menstrual cycle from 5354 women in US…
Thursday, September 27, 2012Frequent discordance was observed between antimullerian hormone and follicle-stimulating hormone, which increased with age in serum from 5,354 women in estradiol-confirmed cycle days 2 to 4.
Thursday, September 27, 2012Reflections on "Addition of recombinant follicle-stimulating hormone to human chorionic gonadotropin treatment in adolescents and young adults with hypogonadotropic hypogonadism promotes normal testicular growth and may promote early spermatogenesis"
Does ovulation induction with follicle-stimulating hormone still have a future in polycystic ovary syndrome?
Friday, June 8, 2012
Robert John Norman, M.D.…